VIRGINIA RETIREMENT SYSTEMS ET Al Has $2.65 Million Stake in Elanco Animal Health Incorporated $ELAN

VIRGINIA RETIREMENT SYSTEMS ET Al lifted its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 48.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 117,173 shares of the company’s stock after purchasing an additional 38,150 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Elanco Animal Health were worth $2,652,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the stock. Legacy Capital Group California Inc. lifted its position in shares of Elanco Animal Health by 3.1% during the fourth quarter. Legacy Capital Group California Inc. now owns 20,988 shares of the company’s stock worth $475,000 after purchasing an additional 632 shares in the last quarter. AlphaQuest LLC lifted its position in shares of Elanco Animal Health by 13.7% during the third quarter. AlphaQuest LLC now owns 5,953 shares of the company’s stock worth $120,000 after purchasing an additional 718 shares in the last quarter. Jones Financial Companies Lllp lifted its position in shares of Elanco Animal Health by 15.2% during the third quarter. Jones Financial Companies Lllp now owns 6,065 shares of the company’s stock worth $119,000 after purchasing an additional 798 shares in the last quarter. US Bancorp DE lifted its position in shares of Elanco Animal Health by 1.9% during the third quarter. US Bancorp DE now owns 43,810 shares of the company’s stock worth $882,000 after purchasing an additional 824 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. lifted its position in shares of Elanco Animal Health by 80.3% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock worth $42,000 after purchasing an additional 900 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Trading Down 0.7%

Shares of NYSE ELAN opened at $21.65 on Friday. The company’s 50 day simple moving average is $23.40 and its 200 day simple moving average is $23.36. Elanco Animal Health Incorporated has a fifty-two week low of $12.40 and a fifty-two week high of $27.72. The firm has a market capitalization of $10.81 billion, a P/E ratio of -43.29, a P/E/G ratio of 2.33 and a beta of 1.69. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.16 and a quick ratio of 1.12.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.06. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The business had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.28 billion. During the same period in the prior year, the business posted $0.37 earnings per share. Elanco Animal Health’s revenue was up 14.9% compared to the same quarter last year. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, analysts predict that Elanco Animal Health Incorporated will post 1.11 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ELAN. JPMorgan Chase & Co. upped their target price on shares of Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Citigroup upped their target price on shares of Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Weiss Ratings lowered shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday. Morgan Stanley upped their target price on shares of Elanco Animal Health from $22.00 to $24.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 25th. Finally, Leerink Partners upped their target price on shares of Elanco Animal Health from $26.00 to $30.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 24th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $28.20.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.